Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19

Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19

Abstract Four COVID-19 vaccines were developed, tested, and authorized early in Europe and the US. Comirnaty and Spikevax are mRNA-based, whereas Jcovden and Vaxzevria utilize adenoviral vectors (AdV). We described a hamster model of COVID-19 utilizing Wuhan-1 strain SARS-CoV-2, in which vaccine-ass...

Full description

Saved in:
Bibliographic Details
Main Authors: Aileen Ebenig, Mona V. Lange, Michelle Gellhorn Serra, Alexandra Kupke, Roland Plesker, Bingqian Qu, Richard J. P. Brown, Thorsten J. Maier, Michael D. Mühlebach
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-025-01100-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41541-025-01100-5

Similar Items